Opportunity Information: Apply for PA 08 267
Apply for PA 08 267
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Oct 8, 2008 and posted on Oct 8, 2008.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments Public and State controlled institutions of higher education Private institutions of higher education Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses For profit organizations other than small businesses Independent school districts County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21) opportunity (Funding Opportunity Number PA 08-267) is a National Cancer Institute (NCI) funding announcement under the National Institutes of Health (NIH) that supports early-stage, innovative research aimed at improving how cancers are found, classified, and predicted. The central goal is to encourage exploratory and developmental studies that propose new or significantly improved approaches for cancer detection, diagnostic characterization, and prognostic assessment, especially when those approaches could reasonably move toward clinical use. Projects are expected to push beyond routine incremental advances and instead test novel ideas, tools, or strategies that could ultimately sharpen clinical decision-making for patients who already have cancer as well as for individuals at elevated risk of developing cancer.
A major scientific emphasis of the announcement is the identification and evaluation of molecular and cellular differences among tumors, premalignant lesions, and normal tissues. The intent is not simply to catalog differences, but to determine which differences matter clinically. Applicants are expected to connect biological findings to real clinical parameters by correlating markers or measurable characteristics with outcomes or clinically relevant features. In practical terms, that means studies should be designed to show translational relevance: how a newly identified molecular signature, cellular phenotype, or tissue characteristic could help solve a defined clinical problem related to detection (finding cancer earlier or more accurately), diagnosis (distinguishing cancer types or subtypes, or separating malignant from benign conditions), treatment planning (informing therapy choices based on tumor characteristics), or prognosis (predicting outcomes such as recurrence risk, progression, or survival). The announcement is therefore geared toward research that bridges basic discoveries and clinical utility, even if the work is still at an exploratory stage.
The mechanism of support is the NIH R21 Exploratory/Developmental Grant, which is commonly used for high-risk, high-reward concepts where preliminary data may be limited but the potential payoff is meaningful. In this specific opportunity, the listed award ceiling is $200,000, and there is no cost sharing or matching requirement. The number of awards is not predetermined; funding depends on the availability of appropriated funds and the quality and volume of applications received, which is typical of NIH program announcements where competition and merit review determine the final slate of funded projects.
Eligibility is broad and includes a wide range of domestic and international organizations. Eligible applicants include state and local governments (including counties, cities, townships, special districts, and independent school districts), public and private institutions of higher education, nonprofits with or without 501(c)(3) status, small businesses, and for-profit organizations other than small businesses. The eligibility language also extends to additional categories such as federal government eligible agencies, faith-based and community-based organizations, Hispanic-serving institutions, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This breadth is intended to attract diverse scientific teams and institutional settings capable of proposing creative, testable ideas in cancer detection and diagnostics research.
Key administrative details from the source record include the posting and creation date of October 8, 2008, with an original and final closing date of September 7, 2012, and an archive date of October 8, 2012. The program is associated with CFDA number 93.394 (Cancer Detection and Diagnosis Research) and is categorized under discretionary grant funding in the health area. For applicants or institutions needing the full archived announcement text, the listing provides a link to the NIH Grants Guide page (http://grants.nih.gov/grants/guide/pa-files/PA-08-267.html) and directs technical access questions to the NIH Office of Extramural Research (OER) webmaster contacts.
FAQs: Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21) (PA 08-267)
What is this funding opportunity?
This is a National Cancer Institute (NCI) funding announcement under the National Institutes of Health (NIH) titled "Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21)." The Funding Opportunity Number is PA 08-267, and it supports early-stage, innovative research intended to improve how cancers are detected, diagnosed/classified, and how patient outcomes are predicted.
What is the main goal of PA 08-267?
The main goal is to encourage exploratory and developmental studies that propose new or significantly improved approaches for cancer detection, diagnostic characterization, and prognostic assessment, particularly approaches that could reasonably move toward clinical use. The announcement prioritizes ideas that go beyond routine incremental advances and instead test novel tools, strategies, or concepts that could improve clinical decision-making.
What types of research does the announcement emphasize?
A major scientific emphasis is identifying and evaluating molecular and cellular differences among tumors, premalignant lesions, and normal tissues. The focus is not only on finding differences, but on determining which differences matter clinically.
Does the opportunity focus on basic science or clinical research?
It is geared toward research that bridges basic discoveries and clinical utility, even when still exploratory. Applicants are expected to connect biological findings to clinical parameters by correlating markers or measurable characteristics with outcomes or clinically relevant features.
What does "translational relevance" mean in the context of this opportunity?
In practical terms, it means designing studies that show how a newly identified molecular signature, cellular phenotype, or tissue characteristic could help solve a defined clinical problem related to detection, diagnosis, treatment planning, or prognosis. The work is expected to demonstrate a plausible path toward clinical usefulness.
What kinds of clinical problems is the research expected to address?
The announcement highlights problems such as finding cancer earlier or more accurately (detection), distinguishing cancer types or subtypes or separating malignant from benign conditions (diagnosis), informing therapy choices based on tumor characteristics (treatment planning), and predicting outcomes such as recurrence risk, progression, or survival (prognosis).
What grant mechanism is used for this opportunity?
The mechanism is the NIH R21 Exploratory/Developmental Grant, which is commonly used for high-risk, high-reward concepts where preliminary data may be limited but the potential payoff is meaningful.
What is the award ceiling for this opportunity?
The listed award ceiling is $200,000.
Is cost sharing or matching required?
No. The opportunity specifies that there is no cost sharing or matching requirement.
How many awards will be made?
The number of awards is not predetermined. Funding depends on the availability of appropriated funds and on the quality and volume of applications received, consistent with typical NIH program announcements where competition and merit review determine which projects are funded.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic and international organizations. Eligible applicants include state and local governments (including counties, cities, townships, special districts, and independent school districts), public and private institutions of higher education, nonprofits with or without 501(c)(3) status, small businesses, and for-profit organizations other than small businesses.
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility language includes non-U.S. entities (foreign organizations).
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are listed among eligible applicant categories.
Are Hispanic-serving institutions included in eligibility?
Yes. Hispanic-serving institutions are explicitly included in the eligibility language.
Can government entities apply, and if so, which ones?
Yes. Eligible government applicants include state governments and local governments, including counties, cities, townships, special districts, and independent school districts. The listing also references federal government eligible agencies.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included as eligible applicant categories.
Is this opportunity still open?
No. The source record lists an original and final closing date of September 7, 2012, and an archive date of October 8, 2012.
When was the opportunity originally posted?
The posting and creation date in the source record is October 8, 2008.
What is the CFDA number associated with this program?
The program is associated with CFDA number 93.394, titled "Cancer Detection and Diagnosis Research."
How is this grant categorized?
It is categorized as discretionary grant funding in the health area.
Where can applicants find the full (archived) announcement text?
The listing provides a link to the NIH Grants Guide page for PA 08-267: http://grants.nih.gov/grants/guide/pa-files/PA-08-267.html
Who should be contacted for technical access questions about the announcement?
The listing directs technical access questions to the NIH Office of Extramural Research (OER) webmaster contacts.
Browse more opportunities from the same category: Education Health
Next opportunity: Webless Migratory Game Bird Research Program
Previous opportunity: Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis (R21/R33)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 08 267
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 08 267) also looked into and applied for these:
| Funding Opportunity |
|---|
| Interactions between Physical Activity and Drug Abuse (R01) Apply for RFA DA 09 013 Funding Number: RFA DA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interactions between Physical Activity and Drug Abuse (R03) Apply for RFA DA 09 014 Funding Number: RFA DA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic and Preclinical Research on Complementary and Alternative Medicine (CAM) (R01) Apply for PA 09 010 Funding Number: PA 09 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Mouse Gene Development Initiative (R01) Apply for RFA DA 09 015 Funding Number: RFA DA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medical Management of Older Patients with HIV/AIDS (R01) Apply for PA 09 017 Funding Number: PA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R01) Apply for PA 09 020 Funding Number: PA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| International Research Collaboration on Drug Abuse and Addiction Research (R21) Apply for PA 09 021 Funding Number: PA 09 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R03) Apply for PA 09 022 Funding Number: PA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R21) Apply for RFA DA 09 018 Funding Number: RFA DA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Secondary Data Analyses for Substance Abuse Research (R21/R33) Apply for RFA DA 09 020 Funding Number: RFA DA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R01) Apply for RFA DA 09 008 Funding Number: RFA DA 09 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R21) Apply for RFA DA 09 009 Funding Number: RFA DA 09 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA RR 09 001 Funding Number: RFA RR 09 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Erythropoiesis Stimulating Agents and Tumor Progression (R01) Apply for PA 09 023 Funding Number: PA 09 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Erythropoiesis Stimulating Agents and Tumor Progression (R21) Apply for PA 09 024 Funding Number: PA 09 024 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute Program Project (P01) Applications Apply for PAR 09 025 Funding Number: PAR 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) Apply for PAR 09 026 Funding Number: PAR 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Education Programs of Excellence in Scientifically Validated Behavioral Treatment (R25) Apply for RFA MH 09 110 Funding Number: RFA MH 09 110 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Shared Instrumentation Grant Program (S10) Apply for PAR 09 028 Funding Number: PAR 09 028 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Mutant Mouse Regional Resource Centers (Limited Competition U42) Apply for RFA RR 09 003 Funding Number: RFA RR 09 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 267", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.